Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Catalyst Grant: Pilot Projects in Aging

University of British Columbia

$50,000.00

Focused stem cell targeting in age-related macular degeneration

FY 2009-10

Summary
Blindness is one of the most severe and debilitating diseases to affect the elderly. Age-related macular degeneration is the commonest reason for blindness in the western world, affecting 4 percent of people over 60 years of age and 25 percent of people over 75 years of age. It is caused by genetic mutation and damage to the macula, a small but very specific area of the retina - the light sensitive layer lining the inner surface of the eyeball. In many cases the only way to repair this damage will be to re-populate the diseased area with new cells. Such cells can also be modified to secrete drugs to protect the macula from further damage. Current methods for targeting new cells to the relevant area of the eye are too imprecise, often deliver too few cells to the targeted area and can in fact cause even more damage to the part of the eye that we are attempting to preserve. New methods of cell targeting are therefore needed. Our preliminary data suggests that new cells, pre-treated with magnetic particles and injected into the eye, can be accurately targeted to the relevant area and in large numbers using an external magnet. We will move these experiments from the laboratory into an animal model of eye disease to assess the feasibility of this approach. We will use different magnetic particles to determine which will be the best for this work. We will also assess different techniques to apply magnets to the outer surface of the eye to see which is the best at focusing cells on the macula. We will use cells derived from bone marrow - an easily accessible source for future trials. We will monitor the injected cells for up to nine months to study how cells migrate and re-populate the targeted tissue and to monitor for any adverse side effects. This preliminary study will form the basis for future trials aimed at improving vision.
Program
Catalyst Grant: Pilot Projects in Aging
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
203981
Name
Gregory-Evans Kevin
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Institute of Aging Pilot Projects
Projecttitle
Focused stem cell targeting in age-related macular degeneration
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$50,000
Cihrequipment2
$0
Programname2
Catalyst Grant: Pilot Projects in Aging
Keyworddelim
Age-Related Macular Degeneration; Blindness; Stem Cells; Treatment
Abstract
Blindness is one of the most severe and debilitating diseases to affect the elderly. Age-related macular degeneration is the commonest reason for blindness in the western world, affecting 4 percent of people over 60 years of age and 25 percent of people over 75 years of age. It is caused by genetic mutation and damage to the macula, a small but very specific area of the retina - the light sensitive layer lining the inner surface of the eyeball. In many cases the only way to repair this damage will be to re-populate the diseased area with new cells. Such cells can also be modified to secrete drugs to protect the macula from further damage. Current methods for targeting new cells to the relevant area of the eye are too imprecise, often deliver too few cells to the targeted area and can in fact cause even more damage to the part of the eye that we are attempting to preserve. New methods of cell targeting are therefore needed. Our preliminary data suggests that new cells, pre-treated with magnetic particles and injected into the eye, can be accurately targeted to the relevant area and in large numbers using an external magnet. We will move these experiments from the laboratory into an animal model of eye disease to assess the feasibility of this approach. We will use different magnetic particles to determine which will be the best for this work. We will also assess different techniques to apply magnets to the outer surface of the eye to see which is the best at focusing cells on the macula. We will use cells derived from bone marrow - an easily accessible source for future trials. We will monitor the injected cells for up to nine months to study how cells migrate and re-populate the targeted tissue and to monitor for any adverse side effects. This preliminary study will form the basis for future trials aimed at improving vision.
Competitiondate
201003
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gregory-Evans, Kevin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $50,000~ $0~
University of British Columbia - $50,000 Grant (2009-… | Canada Spends